Retrospective Study in Patients with Acute HCV treated with Maviret
Research type
Research Study
Full title
A Single-Arm Retrospective Study to Evaluate Safety and Efficacy in Patients with Acute Hepatitis C Virus (HCV) Infection Treated with 8 Weeks of Glecaprevir/Pibrentasvir
IRAS ID
288275
Contact name
Ester Soru
Contact email
Sponsor organisation
AbbVie UK Ltd
Duration of Study in the UK
0 years, 6 months, 31 days
Research summary
Hepatitis C virus (HCV) is a virus in the blood that can cause liver disease, liver damage, and cancer. Glecaprevir and pibrentasvir (GLE/PIB) is currently approved to treat chronic HCV in adult and adolescent patients and works to help stop the virus from multiplying. These drugs are referred to as direct-acting antiviral (DAA) agents. When these two drugs are taken together, they may stop all of the major genotypes (1, 2, 3, 4, 5, and 6) of HCV. There are currently no approved DAA options for use in patients with acute (symptoms occur suddenly) HCV infection. Because of this, treatment is often delayed until the HCV infection is considered chronic (symptoms develop over time).
This study will look back at the medical chart reviews of at least 250 adult and adolescent (aged 12 years and older) patients with acute HCV treated with GLE/PIB. The information will be compared to historical safety and efficacy results for chronic HCV patients treated with GLE/PIB. This aim of this study is to learn how safe and effective a once daily (QD) tablet containing GLE/PIB works in acute HCV patients.
REC name
N/A
REC reference
N/A